{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:35:22Z","timestamp":1793298922478,"version":"4.5.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euf.2026.07.019","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:29:13Z","timestamp":1787257753000},"page":"840-843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Practical Clinical Consultation Guide to Radioligand Therapy in Prostate Cancer"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2126-2838","authenticated-orcid":false,"given":"Jane","family":"McKenzie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Kovaleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8660-4475","authenticated-orcid":false,"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.07.019_b0005","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2967\/jnumed.118.223099","article-title":"Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade","volume":"60","author":"Emmett","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.07.019_b0010","unstructured":"Tagawa S, Sartor O, Piulats J, et al. [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive\/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial. Lancet 2026 Aug 6:S0140-6736(26)01092-5."},{"key":"10.1016\/j.euf.2026.07.019_b0015","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.07.019_b0020","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s43018-026-01140-3","article-title":"Predictive value of early PSMA upregulation for the response to enzalutamide\u2009\u00b1\u2009177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial","volume":"7","author":"Emmett","year":"2026","journal-title":"Nat Cancer"},{"key":"10.1016\/j.euf.2026.07.019_b0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.07.019_b0030","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.07.019_b0035","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.07.019_b0040","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(25)00189-5","article-title":"Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial","volume":"26","author":"Fizazi","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.07.019_b0045","doi-asserted-by":"crossref","unstructured":"Emmett L, Papa N, Sartor O, et al. Prognostic value of interim PSMA-PET total tumor volume for overall survival within ENZA-p, A randomized Phase 2 trial of Enzalutamide versus Enzalutamide Plus [177Lu] Lu-PSMA-617 (ANZUP1901). Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2026.03.026.","DOI":"10.1016\/j.eururo.2026.03.026"},{"key":"10.1016\/j.euf.2026.07.019_b0050","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1200\/JCO-25-02834","article-title":"Trial design and objectives for patients with prostate cancer: recommendations from the Prostate Cancer Working Group 4","volume":"44","author":"Armstrong","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.07.019_b0055","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2967\/jnumed.125.269640","article-title":"Prognostic value of posttherapy SPECT\/CT for overall survival in patients undergoing [177Lu]Lu-PSMA-617 radiopharmaceutical therapy: results from 3 clinical trials","volume":"66","author":"Kashyap","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.07.019_b0060","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.252672","article-title":"177Lu-PSMA-617 SPECT\/CT for early prediction of overall survival in participants with metastatic castration-resistant prostate cancer","volume":"319","author":"Ayati","year":"2026","journal-title":"Radiology"},{"key":"10.1016\/j.euf.2026.07.019_b0065","first-page":"1091","article-title":"Baseline and early on-treatment circulating tumour DNA fraction are a key prognostic biomarker in metastatic castration-resistant prostate cancer treated with [(177)Lu]Lu-PSMA-617","volume":"385","author":"Fettke","year":"2025","journal-title":"Eur Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926001732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926001732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:58:04Z","timestamp":1793296684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926001732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2405456926001732"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.07.019","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical Clinical Consultation Guide to Radioligand Therapy in Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}